Humacyte (NASDAQ:HUMA) Stock Price Breaks Above Fifty Day Moving Average - Here's What Happened

Key Points

• Humacyte shares rose above their 50-day moving average, trading as high as $0.597 and last near $0.59, versus a 50-day average of $0.49.
• Third-quarter results beat expectations: the loss was $0.06 per share versus an expected $0.10, while revenue was $1.03 million versus estimates of about $0.77 million. Symvess sales climbed 151% from Q2, and management expects Q4 sales to at least double Q3.
• Humacyte plans to file a supplemental application for Symvess use in dialysis in November and has begun a first-in-human coronary bypass study. Analyst views are mixed, and a reported $9 million shareholder lawsuit settlement could add a financial cost.

Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) shares crossed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $0.49 and traded as high as $0.5970. Humacyte shares last traded at $0.59, with a volume of 15,631,458 shares trading hands.

Key Humacyte News

Here are the key news stories impacting Humacyte this week:

• Positive Sentiment: Humacyte reported a third-quarter loss of $0.06 per share, narrower than analysts’ expected loss of $0.10. Revenue of $1.03 million also topped estimates of about $0.77 million, though it remains small. Humacyte third-quarter results
• Positive Sentiment: Symvess sales reached $1.0 million in Q3, up 151% from Q2; October sales were $0.8 million. Management expects Q4 sales to at least double Q3, signaling continued commercial adoption. Humacyte sales and filing outlook
• Positive Sentiment: BTIG reaffirmed its Buy rating and $2 price target, reflecting a bullish analyst view, although the target is not a guarantee of future performance. BTIG rating information
• Positive Sentiment: The company said it plans to submit a supplemental biologics license application for dialysis use of Symvess in November. It also highlighted the start of a first-in-human study of its conduit for coronary bypass surgery, though clinical prospects remain uncertain. Humacyte coronary bypass study update
• Negative Sentiment: A report says Humacyte reached a $9 million deal to resolve a shareholder lawsuit. The settlement may create a financial cost even as it removes the case’s ongoing uncertainty. Shareholder lawsuit settlement

Wall Street Analysts Forecast Growth

HUMA has been the topic of a number of research reports. Barclays raised shares of Humacyte to a "hold" rating in a research report on Wednesday, October 7th. Wall Street Zen lowered Humacyte from a "sell" rating to a "strong sell" rating in a report on Saturday, August 15th. Weiss Ratings reissued a "sell (e+)" rating on shares of Humacyte in a research note on Friday, October 2nd. BTIG Research reaffirmed a "buy" rating and issued a $2.00 price objective on shares of Humacyte in a research note on Tuesday. Finally, Benchmark dropped their target price on shares of Humacyte from $2.00 to $1.00 and set a "speculative buy" rating on the stock in a report on Thursday, August 13th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Humacyte presently has an average rating of "Moderate Buy" and an average price target of $4.96.

Humacyte Price Performance

The firm has a market capitalization of $163.90 million, a P/E ratio of -1.20 and a beta of 2.64. The stock's fifty day simple moving average is $0.49 and its 200 day simple moving average is $0.79. The company has a debt-to-equity ratio of 2.07, a current ratio of 6.21 and a quick ratio of 5.74.

Humacyte (NASDAQ:HUMA - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.05). The firm had revenue of $0.41 million during the quarter, compared to the consensus estimate of $1.04 million. Humacyte had a negative net margin of 4,556.29% and a negative return on equity of 983.32%. On average, equities research analysts predict that Humacyte, Inc. will post -0.40 EPS for the current year.

Institutional Investors Weigh In On Humacyte

Several institutional investors have recently bought and sold shares of the company. Alyeska Investment Group L.P. acquired a new position in shares of Humacyte during the second quarter worth $4,700,000. BlackRock Inc. purchased a new stake in Humacyte during the 2nd quarter worth approximately $3,777,000. GSA Capital Partners LLP purchased a new stake in Humacyte during the 2nd quarter worth approximately $785,000. Private Advisor Group LLC purchased a new stake in Humacyte during the 3rd quarter worth approximately $491,000. Finally, HBK Investments L P acquired a new position in Humacyte during the 2nd quarter valued at approximately $617,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

About Humacyte

Humacyte, Inc. is a biotechnology company developing bioengineered human tissues for use in regenerative medicine and vascular repair. The company's platform is designed to create implantable, off-the-shelf tissues that can be stored and used when needed without requiring the collection of tissue from the patient. Its primary product is SYMVESS, an acellular tissue-engineered vessel intended to replace or repair damaged blood vessels. In December 2024, the U.S. Food and Drug Administration approved SYMVESS for use in the urgent treatment of extremity arterial injuries when emergency vascular reconstruction is required.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.